Paul F. Pinsky, Amanda Black, Robert Grubb, E. David Crawford, Gerald Andriole, Ian Thompson and Howard Parnes Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trials Cancer 119
Article first published online: 14 AUG 2012 | DOI: 10.1002/cncr.27774
The Prostate Cancer Prevention Trial (PCPT) and Reduction by Dutasteride of Prostate Cancer Events (REDUCE) chemoprevention trials demonstrated substantial overall reductions in prostate cancer incidence but hints of an increased rate of high-grade disease. A projection of the mortality outcomes of these trials suggests a possibly modest mortality benefit for these agents and, at worst, a small mortality excess.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field
Copyright © 1999–2013 John Wiley & Sons, Inc. All Rights Reserved.